# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
JP Morgan analyst Rachel Vatnsdal maintains Repligen (NASDAQ:RGEN) with a Overweight and lowers the price target from $230 t...
Repligen (NASDAQ:RGEN) reported quarterly earnings of $0.28 per share which missed the analyst consensus estimate of $0.30 by 6...
U.S. stocks were lower, with the Dow Jones index falling around 100 points on Monday.
Repligen posts Q4 2023 results. CEO Tony Hunt highlights order strength in Filtration and Analytics. Positive momentum in new m...